Serina Therapeutics Inc. (SER)
SER trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.82
-6.19% on the day
Market cap
$46.2M
Nano cap
Revenue · 2025
$130K
+132.1% on 2024
Net income · 2025
-$19.2M
-14755.4% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | SER on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001708599 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | AL |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $130K |
| Net income | -$19.2M |
| Operating income | -$24.0M |
| Net margin | -14755.4% |
| Operating margin | -18478.5% |
| Revenue growth | +132.1% |
| Cash | $3.1M |
| Total assets | $7.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 355.6× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-1 | 2026-08-24 |
| Latest annual report | 10-K/A | 2026-03-27 |
| Latest quarterly / interim | 10-Q | 2026-08-13 |
| Latest current report | 8-K | 2026-10-09 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 518 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CELU | Celularity Inc. | $1.42 | -3.40% | $46.1M |
| ANVS | Annovis Bio Inc. | $1.06 | -7.83% | $45.2M |
| ACET | Adicet Bio Inc. | $5.11 | -7.59% | $47.8M |
| ELTX | Elicio Therapeutics Inc. | $1.77 | -5.85% | $48.0M |
| HOWL | Werewolf Therapeutics Inc. | $0.9911 | +0.95% | $48.2M |
| CLNN | Clene Inc. | $3.39 | -7.88% | $48.2M |
| DWTX | Dogwood Therapeutics Inc. | $1.30 | -5.11% | $44.2M |
| IBIO | iBio Inc. | $0.7818 | -13.44% | $50.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier